VERAXA Biotech AG (NASDAQ: VRXA) has begun cell line development for its lead BiTAC(R) T-cell engager (BiTAC(R)-TCE) program, the company announced. The company selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. This collaboration represents an important development milestone, supporting manufacturing, analytical development, and nonclinical studies required before clinical testing.
VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. VERAXA Biotech, an emerging leader in designing novel cancer therapies, is preparing its most advanced oncology candidate for future clinical development.
According to VERAXA, the partnership with ATUM is intended to support the advancement of the lead BiTAC(R)-TCE candidate toward IND/CTA-enabling studies. The Leap-In Transposase(R) technology is expected to enable efficient generation of stable cell lines, which are critical for consistent manufacturing of biologic therapeutics. This step is a key part of the drug development process, as cell line development directly impacts the scalability and reproducibility of the final product.
For investors, the latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
